CRISPR

CRISPR2-smpd1

ID

ZDB-CRISPR-240708-1

Name

CRISPR2-smpd1

Previous Names

None

Target

smpd1 (1)

Sequence

5' - AGAGACACAAGCCTCAATCC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "AGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
sh696	smpd1

Expression

Gene expression in Wild Types + CRISPR2-smpd1

No data available

Phenotype

Phenotype resulting from CRISPR2-smpd1

No data available

Phenotype of all Fish created by or utilizing CRISPR2-smpd1

Phenotype	Fish	Conditions	Figures
brain sphingosine increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain sphinganine increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain ubiquinol-cytochrome-c reductase activity decreased process quality, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
whole organism acid sphingomyelin phosphodiesterase activity decreased efficacy, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
whole organism sphinganine increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
whole organism beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
brain sphingomyelin increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
whole organism sphingomyelin increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
brain ceramide increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
whole organism N-acylsphinganine-1-phosphocholine increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
whole organism ceramide increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
whole organism sphinganine 1-phosphate increased amount, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 2. from Keatinge et al., 2023
brain NADH dehydrogenase (ubiquinone) activity decreased process quality, abnormal	smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain sphinganine amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain ubiquinol-cytochrome-c reductase activity decreased process quality, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain sphingomyelin increased amount, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
whole organism viability, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 5. from Keatinge et al., 2023
brain cytochrome-c oxidase activity process quality, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain ceramide amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain membrane lipid catabolic process process quality, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain glucosylceramide amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
brain NADH dehydrogenase (ubiquinone) activity process quality, ameliorated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 6. from Keatinge et al., 2023
brain beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide amount, exacerbated	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023
retina microglial cell increased amount, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 4. from Keatinge et al., 2023
brain sphingosine increased amount, abnormal	gba1^sh391/sh391; smpd1^sh696/sh696	standard conditions	Fig. 3. from Keatinge et al., 2023

Citations